Format

Send to

Choose Destination
Int Urol Nephrol. 2017 May;49(5):895-901. doi: 10.1007/s11255-017-1529-7. Epub 2017 Feb 4.

Osteoprotegerin and uremic osteoporosis in chronic hemodialysis patients.

Author information

1
Department of Nephrology, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania. dnmoldovan@yahoo.com.
2
Nephrology and Dialysis Clinic, Emergency County Hospital, "Mihai Manasia", 3-5 Clinicilor Street, Cluj-Napoca, Romania. dnmoldovan@yahoo.com.
3
Department of Nephrology, University of Medicine and Pharmacy "Iuliu Hatieganu", Cluj-Napoca, Romania.
4
Military Hospital Cluj-Napoca, Cluj-Napoca, Romania.
5
Nefromed Dialysis Center Cluj-Napoca, Cluj-Napoca, Romania.

Abstract

INTRODUCTION:

Osteoprotegerin (OPG) is a powerful inhibitor of osteoclast activity, and it plays an important role in bone metabolism. In hemodialysis (HD) patients, the relationship between OPG and bone mineral density (BMD) is important, but remains unclear yet. The study objective was to assess the OPG role related to uremic osteoporosis in HD patients.

METHODS:

This cross-sectional study has been realized on a cohort of 63 chronic HD patients.

INCLUSION CRITERIA:

elderly prevalent HD patients with an age over 55 years old.

EXCLUSION CRITERIA:

previous bone disease or previous renal transplant; neoplasia; parathyroidectomy, hormone replacement therapy. The data regarding demographical and clinical characteristics, including treatments for mineral and cardiovascular complications, were recorded. Serum OPG and mineral markers levels were measured. BMD was assessed by calcaneus quantitative ultrasound; it measured broadband ultrasound attenuation, speed of sound (SOS) and stiffness index (STI).

RESULTS:

The high OPG levels were associated with higher bone mineral density (OPG-SOS P = 0.003; R = 0.37; OPG-STI P = 0.03; R = 0.28). Malnutrition, anemia and advanced age correlated with bone demineralization. Males had higher bone density parameters than females. In patients treated with vitamin D (P = 0.005), the BMD was increased comparing to patients without these treatments.

CONCLUSIONS:

OPG levels had directly correlated with bone mineral density parameters. Our study further confirms the critical role of OPG in the pathogenesis of uremic osteoporosis in ESRD. Whether the increased circulant OPG protect against bone loss in patients undergoing HD remains to be established.

KEYWORDS:

Hemodialysis; Osteoporosis; Osteoprotegerin

PMID:
28161839
DOI:
10.1007/s11255-017-1529-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center